The short version of peptide mapping fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-09 and is reviewed periodically as new material appears.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Inlet: a substrate (typically cellulose) where liquids are dispensed manually. Channels: hydrophilic sub-millimeter networks that guide liquid throughout a device. Flow amplifiers: regions of varying geometry where the flow velocity is modified to impart a steady state flow of controllable velocity Flow resistors: a capillary element used to impart a reduced flow velocity in order to control the residence time of a fluid in a microfluidic device Barriers: hydrophobic regions that prevent fluid from leaving the channel. Outlets: location where a chemical or biochemical reaction takes place.
=== Johanna Bauer === Princess Johanna Bauer (Susanne Wuest) is the mother of Moritz Hunter-Bauer, heir to the family-owned Austrian bank IBN Bauer, with whom Tender is pursuing a merger. Yasmin, Henry and Whitney visit the Bauers' castle in Vienna to sway Moritz, who opposes the merger due to both data privacy concerns and his fascist political and economic beliefs. While on a walk with Johanna, Yasmin makes a deal to allow Moritz to publish his views in one of Lord Norton's columns in exchange for his backing the merger. Yasmin later finds one of Adolf Hitler's paintings in the room Johanna gave her to stay, confirming earlier rumors of the Bauers' ties to the Third Reich. Johanna and Moritz later attend Yasmin's fundraiser dinner in Paris for far-right MP Sebastian Stefanowicz. She and Moritz are seated beside Harper, to whom they make several racist innuendos.
A study of children admitted to hospital in Rawalpindi, Pakistan, found that 52.1% of the bottles their caregivers considered clean were actually contaminated. This occurred even though caregivers reportedly followed many of the recommended cleaning practices for cleaning and sterilizing bottles. The most common mistake was to boil the bottles for less than the minimum time recommended by WHO. Research into the preparation of infant formula in South Korea indicates significant levels of contamination can be transmitted through the handling of spoons and other utensils. Spoons, after being touched, were often left in the formula container, allowing bacteria to spread to the formula in the container. C. sakazakii, S. enterica, and S. aureus, all of which are potentially fatal, were able to surviving for weeks in contaminated infant formula. Understanding how recommendations are interpreted is important: in one study, leaving a bottle in water that had been previously boiled in a kettle was believed to be "boiling" the bottle. Researchers emphasize that health providers need to better educate caregivers; and that practical methods of bottle hygiene need to be suited to use in field settings. For example, in Peru, easy-to-adopt practices like using a bottle brush and detergent gave greater advantages than difficult-to-achieve procedures like boiling a bottle. WHO (which strongly recommends breastfeeding) notes that in cases where bottle feeding is to occur, much better education is needed on how to use bottles.
=== The cell === A standard CV experiment employs a cell fitted with three electrodes: reference electrode, working electrode, and counter electrode. This combination is sometimes referred to as a three-electrode setup. Electrolyte is usually added to the sample solution to ensure sufficient conductivity. The solvent, electrolyte, and material composition of the working electrode will determine the potential range that can be accessed during the experiment. The electrodes are immobile and sit in unstirred solutions during cyclic voltammetry. This "still" solution method gives rise to cyclic voltammetry's characteristic diffusion-controlled peaks. This method also allows a portion of the analyte to remain after reduction or oxidation so that it may display further redox activity. Stirring the solution between cyclic voltammetry traces is important in order to supply the electrode surface with fresh analyte for each new experiment. The solubility of an analyte can change drastically with its overall charge; as such it is common for reduced or oxidized analyte species to precipitate out onto the electrode. This layering of analyte can insulate the electrode surface, display its own redox activity in subsequent scans, or otherwise alter the electrode surface in a way that affects the CV measurements. For this reason it is often necessary to clean the electrodes between scans. Common materials for the working electrode include glassy carbon, platinum, and gold. These electrodes are generally encased in a rod of inert insulator with a disk exposed at one end.
In August 1863, Simon Buckner, the last of a string of Confederate commanders based in Knoxville, evacuated the city. On September 1, the vanguard of Union general Ambrose Burnside entered the city to great fanfare (the unit briefly chased future mayor Peter Staub through the streets). Oliver Perry Temple joyously ran behind the soldiers the length of Gay Street, and pro-Union Mayor James C. Luttrell raised a large American flag he had saved for the occasion. Burnside set up his headquarters at John Hervey Crozier's house at the corner of Gay and Union. Thomas William Humes was reinstalled as rector of St. John's Episcopal, and Brownlow returned to the city and once again began publication of the Whig.
Sources: en.wikipedia.org
Official website UPMC Health Plan website Health Sciences at the University of Pittsburgh ISMETT UPMC Children's Hospital of Pittsburgh UPMC Magee-Womens Hospital Archived June 29, 2007, at the Wayback Machine Video UPMC and the City of Pittsburgh
== Amine protection == Benzyl chloroformate is commonly used in organic synthesis for the introduction of the benzyloxycarbonyl (formerly called carboxybenzyl) protecting group for amines. The protecting group is abbreviated Cbz or Z (in honor of discoverer Zervas), hence the alternative shorthand designation for benzyl chloroformate as Cbz-Cl or Z-Cl. Benzyloxycarbonyl is a key protecting group for amines, suppressing the nucleophilic and basic properties of the N lone pair. This "reactivity masking" property, along with the ability to prevent racemization of Z-protected amines, made the Z group the basis of the Begmann-Zervas synthesis of oligopeptides (1932) where the following general reaction is performed to protect the N-terminus of a serially growing oligopeptide chain:
Alcohol has a long association of military use, and has been called "liquid courage" for its role in preparing troops for battle, anesthetizing injured soldiers, and celebrating military victories. It has also served as a coping mechanism for combat stress reactions and a means of decompression from combat to everyday life.
=== Process of definition === To define the IU for a substance, an international collaborative study is organized by the WHO Expert Committee on Biological Standardization using various assay systems in several laboratories. The main goal of the study is to reach a consensus regarding methods of analysis and the approach to standardization so that results can be compared. The study is performed using highly purified preparations of the substance, typically in lyophilized form, called international reference preparations, or IRPs. Each preparation is divided into precisely weighed samples, with each sample stored in its own ampoule labeled with a code corresponding to the source IRP. Assays are performed using these samples and are calibrated against the previously available IU standard. These results can be quite variable; the final IU value for samples of a given IRP are determined by consensus. The IRP that provides the best results and shows the best long term stability is selected to define the next IU. This IRP is then referred to as the international standard. When a standard sample comes close to depleting, a new standard will have to be found. A new batch of the substance in question is produced and calibrated against the old one, so that the unit still represents the same amount of biological activity. Many substances have undergone several such standard sample changes. The third international standard of prolactin has nearly run out and in 2016 replacement was proposed.
Ni = nitrogen intake in proteins on the test diet Ne(f) = (nitrogen excreted in faeces whilst on the test diet) - (nitrogen excreted in faeces not from ingested nitrogen) Ne(u) = (nitrogen excreted in urine whilst on the test diet) - (nitrogen excreted in urine not from ingested nitrogen) Note:
Sources: en.wikipedia.org
== Properties == Metalloids usually look like metals but behave largely like nonmetals. Physically, they are shiny, brittle solids with intermediate to relatively good electrical conductivity and the electronic band structure of a semimetal or semiconductor. Chemically, they mostly behave as (weak) nonmetals, have intermediate ionization energies and electronegativity values, and amphoteric or weakly acidic oxides. Most of their other physical and chemical properties are intermediate in nature.
== See also == Marooned off Vesta, a short story by Isaac Asimov first published in 1939 Vega (disambiguation) Vespa (disambiguation) Vestal (disambiguation) Vestas, a Danish manufacturer of wind turbines
Tyrphostins such as AG538 and AG1024. These are in early pre-clinical testing. They are not thought to be ATP-competitive, although they are when used in EGFR as described in QSAR studies. These show some selectivity towards IGF-1R over IR. Pyrrolo(2,3-d)-pyrimidine derivatives such as NVP-AEW541, invented by Novartis, which show far greater (100 fold) selectivity towards IGF-1R over IR. Monoclonal antibodies are probably the most specific and promising therapeutic compounds. Teprotumumab is a novel therapy showing significant benefit for Thyroid Eye Disease.
== E == efficacy – empirical – encephalitis – end-stage disease – endemic – endogenous – endoscopy – endotoxin – endpoint – enteric – enteritis – entry inhibitors – Env – envelope – enzyme – enzyme-linked immunosorbent assay (ELISA) – eosinophil – eosinophilic folliculitis – epidemic – epidemiological surveillance – epidemiology – epithelium – epitope – Epstein-Barr virus (EBV) – erythema – erythema multiforme – erythrocytes – etiology – exogenous – exotoxin – expanded access – experimental drug – expression system
On 1 January 1971, commercial production of the first portable digital tablet counters in the world began. John Kirby had filed U.K. Patent number GB1358378(A) on 8 September 1970 and U.S. patent number 3789194 on 9 August 1971. These early electronic counters were designed to help pharmacies replace the common (but often inaccurate) practice of counting medications by hand.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.